Some Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shareholders may be a little concerned to see that the Founder, Thomas Gad, recently sold a substantial US$841k worth of stock at a price of US$12.02 per share. That's a big disposal, and it decreased their holding size by 17%, which is notable but not too bad.

Y-mAbs Therapeutics Insider Transactions Over The Last Year

Notably, that recent sale by Founder Thomas Gad was not the only time they sold Y-mAbs Therapeutics shares this year. Earlier in the year, they fetched US$6.83 per share in a -US$1.0m sale. That means that an insider was selling shares at slightly below the current price (US$12.05). When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. It is worth noting that this sale was only 29% of Thomas Gad's holding.

In the last year Y-mAbs Therapeutics insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

I will like Y-mAbs Therapeutics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Insider Ownership Of Y-mAbs Therapeutics

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. It appears that Y-mAbs Therapeutics insiders own 3.0% of the company, worth about US$16m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At Y-mAbs Therapeutics Tell Us?

Insiders sold Y-mAbs Therapeutics shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 3 warning signs for Y-mAbs Therapeutics (of which 1 is a bit concerning!) you should know about.

Of course Y-mAbs Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com